CRUMLIN, UNITED KINGDOM - Jul 1, 2014 - The TGA has cleared a test developed by
Randox Laboratories which allows assessment of the risk of patients
developing Type 2 diabetes and Cardiovascular Disease.
Randoxs biochemistry Adiponectin assay uses Latex Enhanced
Immunoturbidimetric technology, bringing a superior option for
Adiponectin assessment to the clinical diagnostics
market.
Adiponectin is a protein hormone produced and secreted
exclusively by adipocytes. It regulates the metabolism of lipids
and glucose, and influences the bodys response to insulin.
Adiponectin also has anti-inflammatory effects on the cells lining
the walls of blood vessels. Low levels of Adiponectin therefore can
be indicative of insulin resistance (leading to type 2 diabetes)
and Cardiovascular Disease. Low adiponectin levels have also been
shown to correlate with increased likelihood of a woman developing
gestational diabetes in pregnancy.
Randox also offers 2 levels of adiponectin controls as well as
an adiponectin calibrator, delivering a complete testing
package.
Randox Laboratories Managing Director, Dr Peter FitzGerald
said:
Its clear that in the 21st Century increasingly sedentary and
deskbound lifestyles are driving chronic conditions such as
diabetes and cardiovascular disease. 382 million people currently
live with diabetes across the world and according to the
International Diabetes Federation, this figure is predicted to rise
by 55% by 2015. Adiponectin assesses an individuals risk of
development diabetes, and allows resources and treatment to be
focused on those patients most at risk. This highly targeted
strategy should help to decrease the number the people becoming
diabetic, while using resources most effectively.
Ends
Notes to Editors:
Randox Adiponectin is a Latex Enhanced Immunoturbidimetric
assay, wich can be run on multiple clinical chemistry analysers. It
has an assay time of approximately 10 minutes, and a correlation of
r=0.996 with the ELISA method.
Contact Louise McVicker, Public Relations, for further
information atlouise.mcvicker@randox.comor on +44 (0) 28 9445 1016. www.randox.com